Cancer research in India: Challenges &amp; opportunities

Singh, Mayank; Prasad, Chandra Prakash; Singh, Thoudam Debraj; Kumar, Lalit

doi:10.4103/ijmr.ijmr_1711_18

Cited by 50 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A majority of patients with ovarian cancer are diagnosed at an advanced stage, wherein the 5-year survival is < 30%. 4 - 7 Family history of ovarian or breast cancer is one of the important predisposing factors, with first- and second-degree relatives having four-fold and two-fold higher risk of developing ovarian cancer, respectively. 8 - 10 Inherited mutations in the key tumor suppressor genes, the breast cancer susceptibility gene 1 or 2 ( BRCA1 or BRCA2 ), are prevalent in 3%-27% of patients with ovarian cancer who are not selected on the basis of clinical features like family history.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study

Gupta

Rajappa

Advani

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE There are deficient data on prevalence of germline mutations in breast cancer susceptibility genes 1 and 2 ( BRCA1/ BRCA2) in Indian patients with ovarian cancer who are not selected by clinical features. METHODS This prospective, cross-sectional, noninterventional study in nine Indian centers included patients with newly diagnosed or relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer. The primary objective was to assess the prevalence of BRCA1/ BRCA2 mutations, and the secondary objective was to correlate BRCA1/ BRCA2 status with clinicopathologic characteristics. Mutation testing was performed by a standard next-generation sequencing assay. RESULTS Between March 2018 and December 2018, 239 patients with a median age of 53.0 (range, 23.0-86.0 years) years were included, of whom 203 (84.9%) had newly diagnosed disease, 36 (15.1%) had family history of ovarian or breast cancer, and 159 (66.5%) had serous subtype of epithelial ovarian cancer. Germline pathogenic or likely pathogenic mutations in BRCA1 and BRCA2 were detected in 37 (15.5%; 95% CI, 11.1 to 20.7) and 14 (5.9%; 95% CI, 3.2 to 9.6) patients, respectively, whereas variants of uncertain significance in these genes were seen in four (1.7%; 95% CI, 0.5 to 4.2) and six (2.5%; 95% CI, 0.9 to 5.4) patients, respectively. The prevalence of pathogenic or likely pathogenic BRCA mutations in patients with serous versus nonserous tumors, with versus without relevant family history, and ≤ 50 years versus > 50 years, were 40 of 159 (25.2%; 95% CI, 18.6 to 32.6) versus 11 of 80 (13.8%; 95% CI, 7.1 to 23.3; P = .0636), 20 of 36 (55.6%; 95% CI, 38.1 to 72.1) versus 41 of 203 (20.2%; 95% CI, 14.9 to 26.4; P < .0001), and 20 of 90 (22.2%; 95% CI, 14.1 to 32.2) versus 31 of 149 (20.8%; 95% CI, 14.6 to 28.2; P = .7956), respectively. CONCLUSION There is a high prevalence of pathogenic or likely pathogenic germline BRCA mutations in Indian patients with ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study

Gupta

Rajappa

Advani

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…Not only India has a high cancer burden, the majority (75-80%) of cancer patients have advanced disease (Stage 3-4) at the time of diagnosis owing to lack of screening services in most part of the country. Rural areas of India (where 69% of the total population resides) have an even worse situation, where cancer patients and families have to travel long distances to receive treatment and care at a tertiary care oncology center [32].…”

Section: Impact Of Covid-19 On Cancer Screening In Indiamentioning

confidence: 99%

Impact of COVID-19 Pandemic on Cancer Screening in India: Current Situation, Challenges and Way Forwards

Bashar

Begam²

2021

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Cancer screening is a highly effective preventive measure that can reduce cancer incidence and mortality. COVID-19 pandemic has severely disrupted the ongoing screening activities for early diagnosis of cancers across the globe and the worst affected are low and middle income countries and India is no exception to it. This disruption to cancer screening services may have a significant impact on patients, health care practitioners, and health systems. Through this paper, we aim to offer a comprehensive view on the impact of COVID-19 on cancer screening in India and offer potential solutions to the problems arising out of the COVID-19 pandemic in cancer screening and prevention.

show abstract

“…The increased incidence of OPMDs and Oral Squamous Cell carcinoma (OSCC) in the Indian subcontinent is mainly attributed to the prevalence of tobacco usage among varied age groups. Apart from various forms of tobacco, chewing paan with areca nut contributes to oral malignancy, especially in the northeastern parts of India, leading to the high incidence of OSCC [7]. Global Adult Tobacco Survey (GATS) uses a standard and globally accepted protocol for monitoring adult smoking and smokeless tobacco use across countries, including India.…”

Section: Introductionmentioning

confidence: 99%

In Vivo Imaging-Based Techniques for Early Diagnosis of Oral Potentially Malignant Disorders—Systematic Review and Meta-Analysis

Mazur

Ndokaj

Venugopal

et al. 2021

IJERPH

View full text Add to dashboard Cite

Objectives: Oral potentially malignant disorders (OPMDs) are lesions that may undergo malignant transformation to oral cancer. The early diagnosis and surveillance of OPMDs reduce the morbidity and mortality of patients. Diagnostic techniques based on medical images analysis have been developed to diagnose clinical conditions. This systematic review and meta-analysis aimed to evaluate the efficacy of imaging-based techniques compared to the gold standard of histopathology to assess their ability to correctly identify the presence of OPMDs. Design: Literature searches of free text and MeSH terms were performed using MedLine (PubMed), Scopus, Google Scholar, and the Cochrane Library (from 2000 to 30 June 2020). The keywords used in the search strategy were: (“oral screening devices” or “autofluorescence” or “chemiluminescence” or “optical imaging” or “imaging technique”) and (“oral dysplasia” or “oral malignant lesions” or “oral precancerosis”). Results: The search strategy identified 1282 potential articles. After analyzing the results and applying the eligibility criteria, the remaining 43 papers were included in the qualitative synthesis, and 34 of these were included in the meta-analysis. Conclusions: None of the analyzed techniques based on assessing oral images can replace the biopsy. Further studies are needed to explore the role of techniques-based imaging analysis to identify an early noninvasive screening method.

show abstract

Cancer research in India: Challenges & opportunities

Cited by 50 publications

References 16 publications

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study

Impact of COVID-19 Pandemic on Cancer Screening in India: Current Situation, Challenges and Way Forwards

In Vivo Imaging-Based Techniques for Early Diagnosis of Oral Potentially Malignant Disorders—Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About